Explore this issueFebruary 2012
I have thoroughly enjoyed your thoughts under “Rheuminations” in The Rheumatologist and will greatly miss them, particularly your rambling travelogues.
However, I must point out an error in your essay in the December 2011 issue that involves me. You state, “although IL-1Ra was conceived initially as a sepsis drug, it got its first approval for rheumatoid arthritis.” The last part of this statement is correct but the first part is in error.
After my laboratory observed IL-1 inhibitory bioactivity in the supernatants of monocytes cultured on adherent IgG in 1984, for three years we were unsuccessful in purifying the protein because of a loss in bioactivity during chromatography. In 1987, I formed a scientific collaboration with scientists at Synergen, a biotech company in Boulder, specifically to purify the protein from monocyte supernatants prepared by my lab, and to clone and express the cDNA to perform studies on RA.